Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 9/20 | 0.59 |
| ▸ | MGAM | O43451 | 6/20 | 0.59 |
| ▸ | SI | P14410 | 3/20 | 0.59 |
| ▸ | GBA1 | P04062 | 2/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | LCT | P09848 | 1/20 | 0.59 |
| ▸ | GBA2 | Q9HCG7 | 8/20 | 0.53 |
| ▸ | UGCG | Q16739 | 3/20 | 0.53 |
| ▸ | AGL | P35573 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9426822 | 1.00 | GAA (0.59) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL366469 | 1.00 | GAA (0.59) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL2265507 | 0.82 | GAA (0.66) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL18709118 | 0.81 | GAA (0.59) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL17128703 | 0.79 | GAA (0.66) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL26679472 | 0.78 | GAA (0.70) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL2270637 | 0.78 | GAA (0.70) | GAAMGAMSIGBA1TDP1 | |
| Methane SCHEMBL9426826 | 0.77 | GAA (0.36) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL2274019 | 0.76 | GAA (0.68) | GAAMGAMSIGBA1TDP1 | |
| SCHEMBL23996577 | 0.76 | GAA (0.49) | GAAMGAMSIGBA1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703744-B2 | Cholesterol level lowering liposomes | THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2014-04-22 | — | — | US | disclosed |
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | THE CHANCELLORS, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (GB) | 2013-08-01 | — | — | US | disclosed |
| US-20120237592-A1 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES | UNIVERSITY OF OXFORD | 2012-09-20 | — | — | US | disclosed |
| EP-2410989-A2 | CHOLESTEROL LEVEL LOWERING LIPOSOMES | The Chancellor, Masters and Scholars of the University of Oxford (GB) | 2012-02-01 | — | — | EP | disclosed |
| EP-2399587-A1 | Liposome treatment of viral infections | The University of Oxford (GB) | 2011-12-28 | — | — | EP | disclosed |
| EP-2356990-A2 | Liposome treatment of viral infections | University of Oxford (GB) | 2011-08-17 | — | — | EP | disclosed |
| US-20110182982-A1 | LIPOSOME TREATMENT OF VIRAL INFECTIONS | UNIVERSITY OF OXFORD | 2011-07-28 | — | — | US | disclosed |
| EP-2282723-A2 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES | University of Oxford (GB) | 2011-02-16 | — | — | EP | disclosed |
| US-20100266678-A1 | CHOLESTEROL LEVEL LOWERING LIPOSOMES | UNIVERSITY OF OXFORD | 2010-10-21 | — | — | US | disclosed |
| WO-2010109330-A2 | CHOLESTEROL LEVEL LOWERING LIPOSOMES | UNIVERSITY OF OXFORD (GB) | 2010-09-30 | — | — | WO | disclosed |
| US-20090252785-A1 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES | UNIVERSITY OF OXFORD | 2009-10-08 | — | — | US | disclosed |
| WO-2009118658-A2 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES | UNIVERSITY OF OXFORD (GB) | 2009-10-01 | — | — | WO | disclosed |
| EP-2054076-A2 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | United Therapeutics Corporation (US) | 2009-05-06 | — | — | EP | disclosed |
| EP-2049126-A2 | LIPOSOME TREATMENT OF VIRAL INFECTIONS | United Therapeutics Corporation (US) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008088581-A2 | LIPOSOME TREATMENT OF VIRAL INFECTIONS | UNITED THERAPEUTICS CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080138351-A1 | LIPOSOME TREATMENT OF VIRAL INFECTIONS | UNITED THERAPEUTICS CORPORATION | 2008-06-12 | — | — | US | disclosed |
| US-20080131398-A1 | Glucosidase inhibitors; interferons; antifibrotics; hepatitis | UNITED THERAPEUTICS CORPORATION | 2008-06-05 | — | — | US | disclosed |
| WO-2008063727-A2 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | UNITED THERAPEUTICS CORPORATION (US) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237592-A1 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES | LNPK, ERP44, ERP29 | GAA 446/4885MGAM 3390/4885SI 3966/4885 |
| US-20080138351-A1 | LIPOSOME TREATMENT OF VIRAL INFECTIONS | LNPK, MAVS, DNAJA3 | GAA 852/4885MGAM 2631/4885SI 423/4885 |
| US-20110182982-A1 | LIPOSOME TREATMENT OF VIRAL INFECTIONS | LNPK, MAVS, DNAJA3 | GAA 852/4885MGAM 2631/4885SI 423/4885 |
| US-20080131398-A1 | Glucosidase inhibitors; interferons; antifibrotics; hepatitis | GBA3, EIF2AK2, GAA | GAA 3/4885MGAM 13/4885SI 60/4885 |
| US-20100266678-A1 | CHOLESTEROL LEVEL LOWERING LIPOSOMES | NPC1L1, LIPA, CETP | GAA 320/4885MGAM 2273/4885SI 1027/4885 |
| US-20090252785-A1 | ENDOPLASMIC RETICULUM TARGETING LIPOSOMES | LNPK, ERP44, ERP29 | GAA 446/4885MGAM 3390/4885SI 3966/4885 |
| US-20130195798-A1 | COMBINATION THERAPY FOR TREATMENT OF VIRAL INFECTIONS | EIF2AK2, ZC3HAV1, HAVCR2 | GAA 619/4885MGAM 2295/4885SI 2110/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.